OGA inhibitors such as MK-8719 from Merck/Alectos, ASN-120,290 from Asceneuron S.A., and LY-3,372,689 from Eli Lilly are currently in Phase I or II clinical trials to increase O-GlcNAcylation of tau and prevent tau phosphorylation for the treatment of AD (Selnick et al., 2019; Shcherbinin et al., 2020; Permanne et al., 2022). Here, OGA is linked to Alzheimer disease.